Danes to tackle device and pharmaceutical packaging:
This article was originally published in Clinica
The Danish medical device association (DMDA) and the pharmaceutical association (Lif) have established a joint working group to discuss how packaging used in the two industries can be reduced. The group has decided to lay down a set of guidelines, outlining how the medical device industry should implement the EU Packaging Directive. The group has a current membership of 14.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.